share_log

個別銘柄のひと口情報

Individual stock information.

Kabushiki Shimbun ·  Mar 24 07:28

Kei Pharma<4896.T>

The stock has reached its limit-up buy demand. The company, along with Keio University School of Medicine, announced new research results last weekend on the 21st regarding regenerative medicine targeting subacute spinal cord injuries, which is one of the development pipelines (new drug candidates) for regenerative medicine. In clinical research using iPS cell-derived neural precursor cells, improvements were observed in two out of four patients.

Syphus<4892.T>

The Tokyo Stock Exchange lifted the margin trading measures for transactions of the company's stock starting from the trades on the 24th. The Tokyo Stock Exchange had implemented a measure to...

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 282

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.